ClinicalTrials.Veeva

Menu

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

T

The Center for Clinical and Cosmetic Research

Status and phase

Completed
Phase 2

Conditions

Facial Cutaneous Squamous Cell Carcinoma in Situ

Treatments

Combination Product: Aminolevulinic Acid 20% Topical Solution with Blue Light

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06159842
CCCR 03-2023

Details and patient eligibility

About

The goal of this clinical trial is to test how safe and effective it is to treat early form of cancer cells found in the upper skin layer of the face, using a light-sensitive cream used in combination with a light source.

The main questions this trial aims to answer are:

  • to confirm using laboratory testing, how much of the affected facial skin cancer section the treatment was able to remove, and;
  • seeing how many participants had no remaining affected facial skin cancer sections after treatment.

Participants who qualify will be asked to complete 12 visits in total and will receive a total of two treatments, after voluntarily consent has been given.

Full description

In the study, participants will be asked to complete the following:

  • Provide basic personal information (including date of birth, gender, race and ethnicity)
  • Provide their medical/ surgical history and perform a medical exam (including but not limited to physical exam, skin type, vital signs, height, weight and urine pregnancy test collection)
  • Follow study rules such as avoiding certain medications and treatments
  • Allow photographs of the area of skin cancer being treated on the face
  • Provide information on any medications, treatments or reactions that started after the study began
  • Allow two treatments on the skin cancer area of the face using a light-sensitive cream used in combination with a light source
  • Allow clinical documentation of the treatment, such as how well the treatment was tolerated, any skin reaction or side effects
  • Allow surgery to remove the skin cancer area from the face for Laboratory testing

To qualify for this trial, participants must:

  • be an adult (18 years of age or older)
  • give voluntary written consent
  • have a recently diagnosed (less than six months from first visit) skin cancer area on the face that meets surgery size requirements
  • be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas
  • (if female) not be pregnant before and during the study and agree to use acceptable forms of birth control
  • confirm they are not sensitive to any of the study treatment ingredients

All surgery samples collected from the participants towards the end of the study will be sent to a laboratory for testing. All photographs of the treatment area collected during the study will be used as study data.

All participants have the right to refuse further participation in the study at any time.

Enrollment

32 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Must be an adult (18 years of age or older)
  • Voluntary written consent required
  • Must have a recently diagnosed (no more than six months from first study visit) facial isSCC lesion that meets surgery excision size requirements
  • Cannot have other dermatological disease in the isSCC target area
  • Must be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas
  • If female, cannot be pregnant before and during the study and agree to use acceptable forms of birth control

Exclusion criteria

  • Sensitive to any of the study treatment ingredients
  • Pregnant or lactating
  • Medical laboratory evidence of other non-isSCC tumor in the target lesion biopsy specimen
  • History of recurrence in the target isSCC lesion
  • Medical laboratory evidence of certain growth patterns in the target lesion biopsy specimen
  • Chronic medical condition that in the Investigators opinion will interfere in the trial or affect participant safety

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

32 participants in 1 patient group

Photodynamic Therapy (Blue light dose 10 J/cm2 at 10 mW/cm2)
Experimental group
Description:
30 participants will be enrolled to this arm
Treatment:
Combination Product: Aminolevulinic Acid 20% Topical Solution with Blue Light

Trial contacts and locations

1

Loading...

Central trial contact

Clinical Coordinator

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems